News und Analysen
Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205 – the “Company”) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
ABEO achieves a gradual recovery in Q2 2020/21
ABEO, a world leader in sports and leisure equipment, today announces its revenue and order intake for the first half of its 2020/21 financial year (from 1 April to 30 September 2020).
€m
GROUPE BOGART : Q3 2020 turnover of EUR 60.5 million // Sequential business improvement and prudent management in face of the health crisis evolution
PRESS RELEASE
Paris, 13 November 2020
Revenues in € million (unaudited) 2019 2020 Change Q3 turnover 67.9 60.5 -10.9% Fragrance/Cosmetic brands 11.0 10.3 -6.4%
ECA : French logistics supplier IDEA has chosen ECA GROUP's Autonomous Guided Vehicle (AGV) indoor and outdoor - a new range of autonomous logistics vehicles to be brought on the market
ECA GROUP was awarded a contract to provide an indoor and outdoor Autonomous Guided Vehicle (AGV) L-S 1PT for the supply chain provider IDEA operating on large industrial sites like shipyards,
NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy
NANOBOTIX (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo
Société de la Tour Eiffel accelerates its refocusing with the sale of the Dorian Shopping Mall in Saint-Etienne
Société de la Tour Eiffel, a benchmark player in office property in Greater Paris and regional cities in France with high potential, has announced the sale of the Dorian Shopping Mall, located in
NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Verimatrix lanciert neue Markenkampagne: Security Made for People
Verimatrix, (Paris: VMX) (Euronext Paris: VMX), ein global tätiger Anbieter von Sicherheitslösungen zur Unterstützung von Menschen in der modernen vernetzten Welt, präsentierte heute seine neue
Transgene And BioInvent Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b/2 Trial of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers at SITC 2020
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the presentation of the detailed
Verimatrix Launches New Brand Campaign: Security Made for People
Regulatory News:
Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced its new brand campaign, "Security
WAVESTONE : Declaration according to article 223-16 (AMF)
In accordance with article L233-8 of commercial law, Wavestone informs its shareholders that as of October 31, 2020, its capital was composed of 20,196,492 shares representing 24,358,524 voting
TRONICS : HALF YEAR REVENUE AS OF SEPTEMBER 30, 2020 AND OUTLOOK ON THE RESULT FOR THE FIRST HALF OF FISCAL YEAR 2021
Grenoble, France and Dallas, TX, USA – November 6, 2020 - Tronics, a TDK Group Company that manufactures custom MEMS products and standard inertial sensors for industrial applications, has announced
Transgene Reports Business Update and End Q3 2020 Financial Position
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter
TESSI : 9-month 2020 turnover: EUR 347.5m
Altamir's NAV per share: EUR 28.01 as of 30 September 2020, up 3.3% vs 31 December 2019. Favourable business trends in the third quarter
Paris, 5 November 2020 – Net Asset Value per share stood at €28.01 as of 30 September 2020, after distribution of a dividend of €0.66/share on 28 May 2020.
Against the background of the Covid-19
ATEME : THIRD QUARTER REVENUES 2020
Paris, November 5, 2020 – 17.45 CET
- NINE MONTHS REVENUES OF €43.1 MILLION, DOWN 5%
- POSITIVE GROWTH AND PROFIT EXPECTED ON A FULL YEAR BASIS
- ANEVIA ACQUISITION A GAME CHANGER TO CAPTURE THE OTT
Transgene Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Based Therapies Summit
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that its Executive
DALET : NINE MONTHS REVENUES STABLE AT EUR 39.9 MILLION
Paris, 4 November 2020
RECURRING REVENUES UP 19%
- Third quarter revenues down 9% in the context of health crisis
- Growth in recurring revenues (Subscriptions/Support maintenance) by 10% in Q3
HERIGE : TURNOVER AT SEPTEMBER 30, 2020: EUR 431.9 MILLION
Strong business recovery with growth of 11.3% in the third quarter
French GAAP – € million Turnover 2020(1) 2019 % change Like-for-like(2) Current 1st quarte
OENEO : BUSINESS BACK TO ALMOST STABLE LEVELS IN THE SECOND QUARTER - HIGHLY RESILIENT PERFORMANCE IN THE CONTEXT OF COVID-19
CAST - Growth trajectory confirmed: +5.8%
Growth trajectory confirmed: +5.8%
Revenue in €M 2020 2019 Variation % * Q1 6.63 6.87 -0.24 -3.5% Q2 13.34 11.96 +1.38 +11.6% Q3 7.45 7.08 +0.
ANTALIS (ex ANTALIS INTERNATIONAL) : Implemention of squeeze-out by KPP
Press release
Boulogne-Billancourt, 3 November 2020
Implementation of the squeeze-out following the public tender offer
initiated by Kokusai Pulp & Paper Co., Ltd.
Delisting of Antalis shares from
Quantum Genomics Announces End of Financing Agreement with Negma Group Ltd/Park Partners
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and